SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-24-059072
Filing Date
2024-05-14
Accepted
2024-05-14 07:06:14
Documents
65
Period of Report
2024-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q mura-20240331.htm   iXBRL 10-Q 1653739
2 EX-31.1 mura-ex31_1.htm EX-31.1 15399
3 EX-31.2 mura-ex31_2.htm EX-31.2 15450
4 EX-32.1 mura-ex32_1.htm EX-32.1 9416
5 EX-32.2 mura-ex32_2.htm EX-32.2 9468
  Complete submission text file 0000950170-24-059072.txt   5853171

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT mura-20240331.xsd EX-101.SCH 828928
68 EXTRACTED XBRL INSTANCE DOCUMENT mura-20240331_htm.xml XML 758497
Mailing Address 10 EARLSFORT TERRACE DUBLIN 2 L2 D02 T380
Business Address 10 EARLSFORT TERRACE DUBLIN 2 L2 D02 T380 353 1 905 8020
Mural Oncology plc (Filer) CIK: 0001971543 (see all company filings)

IRS No.: 000000000 | State of Incorp.: L2 | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-41837 | Film No.: 24941429
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)